CytomX Therapeutics Inc (NASDAQ: CTMX) on Tuesday, soared 12.84% from the previous trading day, before settling in for the closing price of $1.09. Within the past 52 weeks, CTMX’s price has moved between $0.83 and $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 28.25% over the past five years. The company achieved an average annual earnings per share of -328.04%. With a float of $76.93 million, this company’s outstanding shares have now reached $78.23 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is 98.88%, operating margin of 5.3%, and the pretax margin is 11.89%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 65.49%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -328.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
CytomX Therapeutics Inc (CTMX) is currently performing well based on its current performance indicators. A quick ratio of 1.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.17, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 3.19 million, a positive change from its year-to-date volume of 2.5 million. As of the previous 9 days, the stock’s Stochastic %D was 82.90%. Additionally, its Average True Range was 0.09.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 57.79%, which indicates a significant decrease from 78.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.90% in the past 14 days, which was higher than the 59.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0666, while its 200-day Moving Average is $1.5753. Nevertheless, the first resistance level for the watch stands at $1.3200 in the near term. At $1.4100, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4800. If the price goes on to break the first support level at $1.1600, it is likely to go to the next support level at $1.0900. The third support level lies at $1.0000 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
Market capitalization of the company is 96.26 million based on 78,259K outstanding shares. Right now, sales total 101,210 K and income totals -570 K. The company made 33,430 K in profit during its latest quarter, and 5,740 K in sales during its previous quarter.
